Menopausal hormone therapy: Is there evidence for cardiac protection? Article DOI:
10.1007/s11255-004-6197-8 Cite this article as: Wenger, N.K. Int Urol Nephrol (2004) 36: 617. doi:10.1007/s11255-004-6197-8 Abstract
Menopausal hormone therapy currently has no evidence-based role in the primary or secondary prevention of cardiovascular disease in women. Repeat analysis of the observational data that corrected for socioeconomic status, educational level, and coronary risk factors; as well as information from randomized clinical trials of menopausal hormone therapy both for healthy women and for women with established coronary heart disease and stroke support this statement. This approach is corroborated by recommendations from the US Food and Drug Administration and the recently released Guidelines for Cardiovascular Prevention for Women of the American Heart Association. The latter Guidelines display the lifestyle and pharmacologic interventions that are appropriate for cardiovascular disease risk reduction for women.
Keywords Cardiovascular disease Estrogen Hormone therapy Progestin Women
Updated from a presentation at the Seventh International Conference on Geriatric Nephrology and Urology, Atlanta, GA, October 10, 2003.
Wenger NK. Menopausal hormone therapy. Is there evidence for cardiac protection? In: Shaw LJ, Redberg RF, eds. Contemporary Cardiology: Coronary Disease in Women: Evidence-Based Diagnosis and Treatment. Totowa, NJ: Humana Press, 2003: 321–348.
Wenger, NK 2003 Coronary heart disease: the female heart is vulnerable. Prog Cardiovasc Dis 46 199 229 Google Scholar Barrett-Connor, E, Grady, D 1998 Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 19 55 72 Google Scholar Humphrey, LL, Chan, BK, Sox, HC 2002 Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 137 273 284 Google Scholar Hulley, S, Grady, D, Bush, T, et al. 1998 For the Heart and Estrogen/progestin Replacement Study (HERS) Research Group.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 605 613 Google Scholar Clarke, SC, Kelleher, J, Lloyd-Jones, H, et al. 2002 A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study. BJOG: An Int J Obstetr Gynaecol 109 1056 1062 Google Scholar Herrington, DM, Reboussin, DM, Brosnihan, KB, et al. 2000 Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343 522 529 Google Scholar Viscoli, CM, Brass, LM, Kernan, WN, et al. 2001 A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345 1243 1249 CrossRef PubMed Google Scholar Grady, D, Herrington, D, Bittner, V, et al. 2002 For the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 49 57 Google Scholar Writing, group for the women’s health initiative investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women.Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288 321 333 Google Scholar Manson, JE, Hsia, J, Johnson, KC, et al. 2003 For the Women’s health initiative investigators.estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 523 534 Google Scholar Shumaker, SA, Legault, C, Rapp, SR, et al. 2003 For the WHIMS Investigators.Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 289 2651 2662 PubMed Google Scholar Rapp, SR, Espeland, MA, Shumaker, SA, et al. 2003 for the WHIMS Investigators.Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 289 2663 2672 Google Scholar Waters, DD, Alderman, EL, Hsia, J, et al. 2002 Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 288 2432 2440 Google Scholar The ESPRIT Team. 2002 Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360 2001 2008 Google Scholar Hodis, HN, Mack, WJ, Azen, SP, et al. 2003 for the Women’s Estrogen–Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group.Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 349 535 545 Google Scholar
http: //www.whi.org/updates/advisory_ea_physicians.htm. Women’s Health Initiative. Accessed March 30, 2004.
US Food and Drug Administration. Center for Drug Evaluation and Research. Estrogen and estrogen with progestin therapies for postmenopausal women. Available at www. fda. gov/cder/drug/infopage/estrogens_progestins/default. htm. Accessed March 3, 2003.
www.fda.gov/bbs/topics/NEWS/2004/NEW01022.html. Accessed February 19, 2004
Mosca, L, Appel, LJ, Benjamin, EJ, et al. 2004 Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109 672 692 Google Scholar Copyright information
© Kluwer Academic Publishers 2004